Mechanisms and Targets at the Intersection of HIV and Substance Use (R01, R21 Clinical Trials Not Allowed)

Funding Agency:
National Institutes of Health

The purpose of this Funding Opportunity Announcement (FOA) is to support research on the discovery and development of novel chemical and biological approaches to prevent and/or treat central nervous system (CNS) complications associated with HIV infection and substance use. NIDA is specifically interested in supporting basic research on signaling pathways, virus-host protein interactions, and post-translational protein modifications, which are commonly affected by HIV and substance use and lead to neuropathology and neurocognitive dysfunction.

Although this funding opportunity uses the R01 grant mechanism, it runs in parallel with a program of identical scientific scope, RFA-DA-24-014, which uses the R21 grant mechanism.


  • Letter of Intent Due Date(s): July 09, 2023

  • AIDS Due Date:  Aug 9, 2023

RFA-DA-24-013 Expiration Date August 10, 2023

Agency Website



Amount Description

Application budgets are limited to $400,000 in direct costs per year and need to reflect the actual needs of the proposed project.

The maximum project period is 5 years.

Funding Type





Medical - Basic Science

External Deadline

August 9, 2023